Methods and compositions for contributing to the treatment of cancers
View Patent ↗Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET B ) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
1. A method of selectively increasing delivery of a chemotherapeutic agent to an ovarian tumor comprising administering to a mammal in need thereof an IRL-1620 and a chemotherapeutic agent.
2. The method according to claim 1 , wherein said IRL-1620 selectively increases blood flow to said ovarian tumor thereby increasing said delivery of said chemotherapeutic agent to said ovarian tumor, and wherein said chemotherapeutic agent comprises cyclophosphamide.
3. The method according to claim 1 , wherein the pharmacokinetic properties of said chemotherapeutic agent are not affected by said IRL-1620.
4. The method according to claim 2 , wherein said IRL-1620 enhances the efficacy of said chemotherapeutic agent.
5. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered simultaneously.
6. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered sequentially.
7. The method according to claim 6 , wherein said IRL-1620 is administered at least 15 minutes before said chemotherapeutic agent.
8. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 120 minutes before said chemotherapeutic agent.
9. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 60 minutes before said chemotherapeutic agent.
10. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 30 minutes before said chemotherapeutic agent.
11. The method according to claim 1 , wherein said chemotherapeutic agent is adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, or mixtures thereof.
12. The method according to claim 1 , wherein said chemotherapeutic agent is paclitaxel.
13. The method according to claim 1 , wherein said chemotherapeutic agent is cisplatin.
14. The method according to claim 1 , wherein said chemotherapeutic agent is docetaxel.
15. The method according to claim 1 , wherein said chemotherapeutic agent is carboplatin.